Management of Thrombotic Thrombocytopenic Purpura (TTP)

Pathophysiology and Contraindication in Acute TTP

• TTP is characterized by severe thrombocytopenia, which significantly increases bleeding risk, making antiplatelet therapy potentially dangerous during the acute phase 1
• The primary treatment for acute TTP should focus on plasma exchange and corticosteroids rather than antiplatelet therapy 2

Evidence Against Antiplatelet Use in Acute TTP

• The American Society of Hematology guidelines do not recommend antiplatelet therapy in the emergency management of TTP 2

Emergency Management of TTP

• For life-threatening bleeding in TTP patients, IVIg has the most rapid onset of action and should be considered along with corticosteroids (grade 2B recommendation) 2
• Platelet transfusions may be considered in critical bleeding situations despite theoretical concerns about fueling the thrombotic process 2
• Recombinant factor VIIa has been used in bleeding TTP patients, though with caution due to thrombosis risk 2
• Antifibrinolytic agents (aminocaproic acid and tranexamic acid) have been suggested as adjunct treatments for bleeding, but their efficacy is unproven 2

Potential Role in Maintenance Therapy

• However, this approach is not universally recommended in current guidelines and should be considered only after careful risk assessment 2

Common Pitfalls to Avoid

• Confusing TTP management with that of other thrombotic microangiopathies or myeloproliferative disorders where antiplatelet therapy may be beneficial 3, 4